## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -9.4% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($378.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251209T100909 | Somewhat-Bullish | Relevance: 99%
- The California Public Employees Retirement System increased its stake in Alnylam Pharmaceuticals by 5.0% during the second quarter, acquiring an additional 10,100 shares. This brings their total holdings to 211,581 shares, valued at approximately $68.99 million. Other institutional investors have also adjusted their positions, and insider selling by executives has been noted.

**2. Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251209T140909 | Neutral | Relevance: 98%
-  Thematics Asset Management initiated a new position in Alnylam Pharmaceuticals (NASDAQ:ALNY) during the second quarter, acquiring 6,118 shares valued at approximately $1.995 million. Despite institutional buying, company insiders, including CEO Yvonne Greenstreet and EVP Kevin Fitzgerald, have been selling shares, totaling 60,328 shares worth about $27.3 million in the last 90 days. Analysts currently maintain a "Moderate Buy" consensus rating with an average target price of $482.17, suggesting potential upside from its current trading price near $430.

**3. Alnylam to repurchase $34.4 million of convertible notes**
- Source: Investing.com | 20251211T130950 | Somewhat-Bullish | Relevance: 98%
-  Alnylam Pharmaceuticals (NASDAQ:ALNY) announced an agreement to repurchase approximately $34.4 million of its 1.00% Convertible Senior Notes due 2027 for about $51.9 million, including accrued interest. Following the repurchase, $362.8 million of these Notes will remain outstanding. The company, which specializes in RNA interference therapeutics, maintains a strong financial position with a current ratio of 2.54 and recently reported impressive revenue growth and profitability.

**4. United States Gene Therapy Market to Hit $6510.45 Million by 2033**
- Source: openPR.com | 20251210T130859 | Bullish | Relevance: 98%
- The US Gene Therapy Market is projected to reach $21,701.51 million by 2033, growing at a CAGR of 23.5% from 2025-2033, driven by advancements in viral vectors and precision medicine. Key industry developments include FDA approvals for new gene therapies, commercial launches of sickle cell gene therapies with novel payment models, and expansion of manufacturing centers. The market is segmented by approach (In-Vivo and Ex Vivo), vector type (Viral and Non-Viral), technique (Gene Addition, Gene Silencing, Gene Editing), and application (Rare Diseases, Oncology, Blood Disorders, etc.).

**5. Alnylam Pharmaceuticals, Inc. Announces Partial Repurchase of Convertible Notes**
- Source: TradingView | 20251211T120950 | Neutral | Relevance: 97%
-  Alnylam Pharmaceuticals, Inc. announced a partial repurchase of its convertible senior notes on December 10, 2025. The company repurchased $34.4 million of 1.00% convertible notes due 2027 for a total cost of $51.9 million, leaving approximately $362.8 million of notes outstanding. Capped call transactions remain unaffected by these repurchases.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.5% 5d) with bearish MACD, trend may be turning.
2. Near-term weakness: 9.1% below SMA50 despite long-term uptrend.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 38.9x attractive for 114% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 43% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.5B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 38.9 |
| Current P/E | 83.2 |
| YoY Growth | 113.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -0.9% to -9.4% (-8.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 13.4pp (needs >4.0% for momentum thesis). AM_20 at -7.4% indicates price below own 20MA trend. Underperforming sector by 7.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-4.69), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -9.37% (CS: 2) | Weak |
| RSI_14 | 36.9 | Neutral |
| MACD Histogram | -4.69 | Bearish |
| vs SMA20 | 0.926x | Below |
| vs SMA50 | 0.909x | Below |
| vs SMA200 | 1.143x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $412.63
- **Stop Loss:** $378.61 (8.2% risk)
- **Target:** $446.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $16,505.20
- **Portfolio %:** 16.51%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*